Total Revenue
Incyte Total Revenue decreased by 15.5% to $1.27B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.9%, from $1.05B to $1.27B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 14.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $705.71M | $812.99M | $862.85M | $733.24M | $911.40M | $823.30M | $926.70M | $808.67M | $954.61M | $919.03M | $1.01B | $880.89M | $1.04B | $1.14B | $1.18B | $1.05B | $1.22B | $1.37B | $1.51B | $1.27B |
| QoQ Change | — | +15.2% | +6.1% | -15.0% | +24.3% | -9.7% | +12.6% | -12.7% | +18.0% | -3.7% | +10.3% | -13.1% | +18.5% | +9.0% | +3.6% | -10.7% | +15.4% | +12.4% | +10.3% | -15.5% |
| YoY Change | — | — | — | — | +29.1% | +1.3% | +7.4% | +10.3% | +4.7% | +11.6% | +9.3% | +8.9% | +9.3% | +23.8% | +16.3% | +19.5% | +16.5% | +20.0% | +27.8% | +20.9% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| JAKAFI | $705.97M | $741.18M | $773.11M | $709.41M | $763.79M | $791.07M | $828.24M | $757.76M |
| OPZELURA | $121.70M | $139.27M | $161.60M | $118.71M | $164.50M | $187.97M | $207.28M | $143.02M |
| JAKAVI Royalty Revenues | $99.32M | $115.74M | $114.19M | $92.15M | $109.71M | $125.65M | $130.23M | $105.56M |
| NIKTIMVO | — | — | — | $13.61M | $36.15M | $45.83M | $56.04M | $55.09M |
| MINJUVI/MONJUVI | $31.12M | $31.44M | $32.81M | $29.55M | $31.13M | $41.99M | $41.91M | $49.23M |
| ZYNYZ | $651.00K | $694.00K | $1.37M | $3.01M | $8.92M | $22.67M | $31.75M | $41.39M |
| OLUMIANT Royalty Revenues | — | — | — | $30.80M | $33.48M | $37.11M | — | $36.41M |
| ICLUSIG | $26.86M | $29.75M | $27.37M | $29.54M | $32.73M | $37.58M | $34.22M | $35.46M |
| PEMAZYRE | $20.27M | $20.66M | $23.14M | $18.44M | $22.19M | $22.74M | $23.35M | $22.54M |
| Milestone and contract revenues | — | — | $0.00 | $0.00 | $5.00M | $45.00M | $100.00M | $17.00M |
| TABRECTA Royalty Revenues | $5.30M | $5.93M | $6.29M | $6.41M | $6.63M | $6.51M | $7.14M | $5.98M |
| Other product royalty revenues | — | — | — | $1.27M | $1.29M | $1.86M | $3.47M | $3.25M |
| Milestone And Contract Revenue | $0.00 | $18.00M | — | — | — | — | — | — |
| Olumiant Royalty | $31.70M | $34.80M | $38.49M | $36.15M | — | — | $36.15M | — |
| PEMAZYRE Royalty Revenues | $876.00K | $414.00K | $333.00K | — | — | — | — | — |
| Total | $1.04B | $1.14B | $1.18B | $1.05B | $1.22B | $1.37B | $1.51B | $1.27B |
Milestone And Contract Revenue, MINJUVI, Olumiant Royalty, PEMAZYRE Royalty Revenues were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $1.05B | $1.22B | $1.37B | $1.51B | $1.27B |
| Total | $1.05B | $1.22B | $1.37B | $1.51B | $1.27B |
Geographic Breakdown — United States
| Segment | Q2 '21 | Q4 '21 | Q3 '22 | Q2 '24 | Q3 '24 | Q1 '25 |
|---|---|---|---|---|---|---|
| United States | $725.00M | $725.00M | $800.00M | $989.03M | $1.07B | $981.56M |
| Total | $705.71M | $862.85M | $823.30M | $1.04B | $1.14B | $1.05B |
Geographic Breakdown — Europe
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Europe | $53.59M | $66.46M | $88.86M | $68.61M | $78.83M | $100.31M | $75.99M | $92.43M |
| Other countries | — | — | — | $2.73M | $4.35M | $4.41M | $6.08M | $8.78M |
| Total | $1.04B | $1.14B | $1.18B | $1.05B | $1.22B | $1.37B | $1.51B | $1.27B |
Europe and Japan is derived from annual filings.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Incyte's total revenue?
- Incyte (INCY) reported total revenue of $1.27B in Q1 2026.
- How has Incyte's total revenue changed year-over-year?
- Incyte's total revenue increased by 20.9% year-over-year, from $1.05B to $1.27B.
- What is the long-term trend for Incyte's total revenue?
- Over 4 years (2021 to 2025), Incyte's total revenue has grown at a 14.5% compound annual growth rate (CAGR), from $2.99B to $5.14B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities before any expenses.